Cathy Kelly
Senior Writer
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
Drug Pricing Reform In Medicare And Medicaid: Upcoming Regulatory Actions
Two highly anticipated proposed rules in Medicare Part D are scheduled for near-term release.
Government Action/Industry Reaction: HHS Sees Success In Approach To Drug Pricing Solutions
US HHS officials Azar and O’Brien tell a National Academy of Medicine forum that an important element of the Trump Administration’s approach to lowering drug prices is eliciting voluntary change from market players.
Step Therapy For Anti-Inflammatories, ESAs Coming To UnitedHealthcare Medicare Plans
Remicade, Procrit, Aranesp and biosimilars will be subject to step therapy in limited number of Medicare Advantage plans in 2019.
CVS Offering Point-Of-Sale Rebates In Part D Next Year With SilverScript Plan
Premiums will average about $80 for enhanced plan, well above average $32.50 premium for basic stand-alone Medicare Part D coverage in 2019.
GSK Returns To Paid External Experts For Physician Communications
Policy update reverses approach announced in 2013 on the basis that physicians prefer peer-to-peer communications with global expert practitioners, firm explains.
Biosimilars To Be Subject To Same Pay-For-Delay Deal Reporting As Generics
Legislation headed to President Trump would also ban pharmacy "gag" clauses.